Can denosumab be given every 3 months?

Topics: Breast Cancer • Medical Oncology • Endocrinology

With studies showing non inferiority to zoledronic acid q 3 months in support of bone metastatic disease, would you consider extrapolating this data and giving denosumab every 3 months as well?

Answer from: Medical Oncologist at Academic Institution

Not without data. The long half life and persistence of bisphosphonates in the bone is different from the shorter half life of monoclonal antibodies targeting RANK ligand (32 days). So dosing denosumab 120mg every 3 months would probably lead to suboptimal drug levels and increased bone turnover. Wh...

Comments

Medical Oncologist at Yuma Regional Medical Center Cancer Center
RANKL inhibitors have a shorter half-life and as s...

Related Questions